Impact of bromocriptine-QR therapy on cardiovascular outcomes in type 2 diabetes mellitus subjects on metformin

References

• Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham Study. JAMA. 1979;241(19):2035–2038.
   PubMed Web of Science ®Google Scholar
• Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care. 2003;26(Suppl 1):S83–S86.
   PubMedGoogle Scholar
• Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–2222.
   PubMed Web of Science ®Google Scholar
• ADA. Executive summary: standards of medical care in diabetes–2013. Diabetes Care. 2013;36(Suppl 1):S4–S10.
   PubMed Web of Science ®Google Scholar
• Anabtawi A, Miles JM. Metformin: non-glycemic effects and potential novel indications. Endocr Pract. 2016;22(8):999–1007.
   PubMed Web of Science ®Google Scholar
• Garber AJ, Blonde L, Bloomgarden ZT, et al. The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations. Endocr Pract. 2013;19(1):100–106.
   PubMed Web of Science ®Google Scholar
• Vinik AI, Cincotta AH, Scranton RE, et al. Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents. Endocr Pract. 2012;18(6):931–943.
   PubMed Web of Science ®Google Scholar
• Florez H, Scranton R, Farwell WR, et al. Randomized clinical trial assessing the efficacy and safety of bromocriptine-QR when added to ongoing thiazolidinedione therapy in patients with type 2 diabetes mellitus. J Diabetes Metab. 2011; 2(7):142.
   Google Scholar
• Gaziano JM, Cincotta AH, O’Connor CM, et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care. 2010;33(7):1503–1508.
   PubMed Web of Science ®Google Scholar
• Gaziano JM, Cincotta AH, Vinik A, et al. Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects. J Am Heart Assoc. 2012;1(5):e002279.
   PubMed Web of Science ®Google Scholar
• Lorber D. Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2014;7:169–183.
   PubMedGoogle Scholar
• Scranton R, Cincotta A. Bromocriptine–unique formulation of a dopamine agonist for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2010;11(2):269–279.
   PubMed Web of Science ®Google Scholar
• Cincotta AH. Hypothalamic role in the insulin resistance syndrome. In: Hansen B, Shafrir E, editors. Insulin resistance and insulin resistance syndrome; frontiers in animal diabetes research. London: Taylor and Francis; 2002. p. 271–312.
   Google Scholar
• Raskin P, Cincotta AH. Bromocriptine-QR therapy for the management of type 2 diabetes mellitus: developmental basis and therapeutic profile summary. Expert Rev Endocrinol Metab. 2016;11(2):113–148.
   PubMed Web of Science ®Google Scholar
• Luo S, Luo J, Cincotta AH. Suprachiasmatic nuclei monoamine metabolism of glucose tolerant versus intolerant hamsters. NeuroReport. 1999;10:2073–2077.
   PubMed Web of Science ®Google Scholar
• Luo S, Meier AH, Cincotta AH. Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters. Neuroendocrinology. 1998;68(1):1–10.
   PubMed Web of Science ®Google Scholar
• Ezrokhi M, Luo S, Trubitsyna Y, et al. Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats. Diabetol Metab Syndr. 2014;6:104.
   PubMed Web of Science ®Google Scholar
• Bina KG, Cincotta AH. Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in ob/ob mice. Neuroendocrinology. 2000;71(1):68–78.
   PubMed Web of Science ®Google Scholar
• Scislowski PW, Tozzo E, Zhang Y, et al. Biochemical mechanisms responsible for the attenuation of diabetic and obese conditions in ob/ob mice treated with dopaminergic agonists. Int J Obes Relat Metab Disord. 1999;23(4):425–431.
   PubMed Web of Science ®Google Scholar
• Cincotta AH, Luo S, Zhang Y, et al. Chronic infusion of norepinephrine into the VMH of normal rats induces the obese glucose-intolerant state. Am J Physiol Regul Integr Comp Physiol. 2000;278(2):R435–R444.
   PubMed Web of Science ®Google Scholar
• Ezrokhi M, Trubitsyna Y, Luo S, et al. Timed dopamine agonist treatment ameliorates both vascular nitrosative/oxidative stress pathology and aortic stiffness in arteriosclerotic, hypertensive SHR rats. Diabetes. 2010;59(Suppl 1):A67.
   Google Scholar
• Chamarthi B, Vinik AI, Ezrokhi M, et al. Dopamine agonist therapy reduces elevated heart rate and dysglycemia in Type 2 diabetes subjects. Diabetes. 2016;65(Suppl1):A317.
   Google Scholar
• Luo S, Ezrokhi M, Trubitsyna Y, et al. Elevation of norepinephrine (NE) activity at the ventromedial hypothalamus (VMH) of normal rats induces the obese hypertensive insulin resistant state without altering feeding. Diabetes. 2015;64(Suppl1):A540.
   Google Scholar
• Grassi G. Sympathetic overdrive and cardiovascular risk in the metabolic syndrome. Hypertens Res. 2006;29(11):839–847.
   PubMed Web of Science ®Google Scholar
• Lambert GW, Straznicky NE, Lambert EA, et al. Sympathetic nervous activation in obesity and the metabolic syndrome-causes, consequences and therapeutic implications. Pharmacol Ther. 2010;126(2):159–172.
   PubMed Web of Science ®Google Scholar
• Tentolouris N, Liatis S, Katsilambros N. Sympathetic system activity in obesity and metabolic syndrome. Ann N Y Acad Sci. 2006;1083:129–152.
   PubMed Web of Science ®Google Scholar
• Chiodini I, Adda G, Scillitani A. Cortisol secretion in patients with type 2 diabetes: relationship with chronic complications. Diabetes Care. 2007;30(1):83–88.
   PubMed Web of Science ®Google Scholar
• Elenkov IJ, Wilder RL, Chrousos GP, et al. The sympathetic nerve–an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev. 2000;52(4):595–638.
   PubMed Web of Science ®Google Scholar
• Hu A, Jiao X, Gao E, et al. Chronic β-adrenergic receptor stimulation induces cardiac apoptosis and aggravates myocardial ischemia/reperfusion injury by provoking inducible nitricoxide synthase-mediated nitrative stress. J Pharmacol Exp Ther. 2006;318(2):469–475.
   PubMed Web of Science ®Google Scholar
• Palatini P. Sympathetic overactivity in hypertension: a risk factor for cardiovascular disease. Curr Hypertens Rep. 2001;3(Suppl 1):S3–S9.
   PubMedGoogle Scholar
• Palatini P. Elevated heart rate as a predictor of increased cardiovascular morbidity. J Hypertens Suppl. 1999;17(3):S3–S10.
   PubMedGoogle Scholar
• Luo S, Luo J, Cincotta AH. Chronic ventromedial hypothalamic infusion of norepinephrine and serotonin promotes insulin resistance and glucose intolerance. Neuroendocrinology. 1999;70:460–465.
   PubMed Web of Science ®Google Scholar
• Luo S, Luo J, Meier AH, et al. Dopaminergic neurotoxin administration to the area of the suprachiasmatic nuclei induces insulin resistance. Neuroreport. 1997;8:3495–3499.
   PubMed Web of Science ®Google Scholar
• Perin PC, Maule S, Quadri R. Sympathetic nervous system, diabetes, and hypertension. Clin Exp Hypertens. 2001;23(1–2):45–55.
   PubMed Web of Science ®Google Scholar
• Masuo K, Rakugi H, Ogihara T, et al. Cardiovascular and renal complications of type 2 diabetes in obesity: role of sympathetic nerve activity and insulin resistance. Curr Diabetes Rev. 2010;6(2):58–67.
   PubMedGoogle Scholar
• Lambert EA, Lambert GW. Stress and its role in sympathetic nervous system activation in hypertension and the metabolic syndrome. Curr Hypertens Rep. 2011;13(3):244–248.
   PubMed Web of Science ®Google Scholar
• Luo S, Liang Y, Cincotta AH. Intracerebroventricular administration of bromocriptine ameliorates the insulin-resistant/glucose-intolerant state in hamsters. Neuroendocrinology. 1999;69:160–166.
   PubMed Web of Science ®Google Scholar
• Ezrokhi M, Luo S, Trubitsyna Y, et al. Weighted effects of bromocriptine treatment on glucose homeostasis during hyperglycemic versus euglycemic clamp conditions in insulin resistant hamsters: bromocriptine as a unique postprandial insulin sensitizer. J Diab Metab. 2012;S2:007.
   Google Scholar
• Cincotta AH, Meier AH. Bromocriptine inhibits in vivo free fatty acid oxidation and hepatic glucose output in seasonally obese hamsters (Mesocricetus auratus). Metabolism. 1995;44:1349–1355.
   PubMed Web of Science ®Google Scholar
• Pijl H, Ohashi S, Matsuda M, et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care. 2000;23:1154–1161.
   PubMed Web of Science ®Google Scholar
• Luo S, Ezrokhi M, Trubitsyna Y, et al. Intrahypothalamic circuitry regulating hypothalamic fuel sensing to induce insulin sensitivity or insulin resistance. Diabetologia. 2008;51(Suppl1):S59.
   Google Scholar
• O’Keefe JH, Bell DS. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol. 2007;100(5):899–904.
   PubMed Web of Science ®Google Scholar
• Garber AJ. Postprandial dysmetabolism and the heart. Heart Fail Clin. 2012;8(4):563–573.
   PubMed Web of Science ®Google Scholar
• Node K, Inoue T. Postprandial hyperglycemia as an etiological factor in vascular failure. Cardiovasc Diabetol. 2009;8:23.
   PubMed Web of Science ®Google Scholar
• Pastromas S, Terzi AB, Tousoulis D, et al. Postprandial lipemia: an under-recognized atherogenic factor in patients with diabetes mellitus. Int J Cardiol. 2008;126(1):3–12.
   PubMed Web of Science ®Google Scholar
• Bansal S, Buring JE, Rifai N, et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298(3):309–316.
   PubMed Web of Science ®Google Scholar
• Ansar S, Koska J, Reaven PD. Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins. Cardiovasc Diabetol. 2011;10:61.
   PubMed Web of Science ®Google Scholar
• Cincotta AH, Meier AH, Cincotta M Jr. Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs. 1999;8:1683–1707.
   PubMedGoogle Scholar
• Bell DS. Focusing on cardiovascular disease in type 2 diabetes mellitus: an introduction to bromocriptine QR. Postgrad Med. 2012;124(5):121–135.
   PubMed Web of Science ®Google Scholar
• Bell DS. Why does quick-release bromocriptine decrease cardiac events? Diabetes Obes Metab. 2011;13(10):880–884.
   PubMed Web of Science ®Google Scholar
• Bleeke T, Zhang H, Madamanchi N, et al. Catecholamine-induced vascular wall growth is dependent on generation of reactive oxygen species. Circ Res. 2004;94(1):37–45.
   PubMed Web of Science ®Google Scholar
• Kukreja RS, Datta BN, Chakravarti RN. Catecholamine-induced aggravation of aortic and coronary atherosclerosis in monkeys. Atherosclerosis. 1981;40(3–4):291–298.
   PubMed Web of Science ®Google Scholar
• Ramchandra R, Barrett CJ, Malpas SC. Nitric oxide and sympathetic nerve activity in the control of blood pressure. Clin Exp Pharmacol Physiol. 2005;32(5–6):440–446.
   PubMed Web of Science ®Google Scholar
• Bernstein IM, Damron D, Schonberg AL, et al. The relationship of plasma volume, sympathetic tone, and proinflammatory cytokines in young healthy nonpregnant women. Reprod Sci. 2009;16(10):980–985.
   PubMed Web of Science ®Google Scholar
• Schulz E, Gori T, Münzel T. Oxidative stress and endothelial dysfunction in hypertension. Hypertens Res. 2011;34(6):665–673.
   PubMed Web of Science ®Google Scholar
• Gayen JR, Zhang K, RamachandraRao SP, et al. Role of reactive oxygen species in hyperadrenergic hypertension: biochemical, physiological, and pharmacological evidence from targeted ablation of the chromogranin a (Chga) gene. Circ Cardiovasc Genet. 2010;3(5):414–425.
   PubMed Web of Science ®Google Scholar
• Singh MV, Chapleau MW, Harwani SC, et al. The immune system and hypertension. Immunol Res. 2014;59(1–3):243–253.
   PubMed Web of Science ®Google Scholar
• Randriamboavonjy V, Mann WA, Elgheznawy A, et al. Metformin reduces hyper-reactivity of platelets from patients with polycystic ovary syndrome by improving mitochondrial integrity. Thromb Haemost. 2015;114(3):569–578.
   PubMed Web of Science ®Google Scholar
• Arunachalam G, Lakshmanan AP, Samuel SM, et al. Molecular interplay between microrna-34a and sirtuin1 in hyperglycemia-mediated impaired angiogenesis in endothelial cells: effects of metformin. JPET. 2016;356(2):314–323.
   PubMed Web of Science ®Google Scholar
• Xu T, Brandmaier S, Messias AC, et al. Effects of metformin on metabolite profiles and LDL cholesterol in patients with type 2 diabetes. Diabetes Care. 2015;38(10):1858–1867.
   PubMed Web of Science ®Google Scholar
• Ozgurtas T, Oktenli C, Dede M, et al. Metformin and oral contraceptive treatments reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS). Atherosclerosis. 2008;200(2):336–344.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Alexandraki K, Piperi C, et al. Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome. Metabolism. 2007;56(1):129–134.
   PubMed Web of Science ®Google Scholar
• Kocer D, Bayram F, Diri H. The effects of metformin on endothelial dysfunction, lipid metabolism and oxidative stress in women with polycystic ovary syndrome. Gynecol Endocrinol. 2014;30(5):367–371.
   PubMed Web of Science ®Google Scholar
• Giugliano D, De Rosa N, Di Maro G, et al. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care. 1993;16(10):1387–1390.
   PubMed Web of Science ®Google Scholar
• Manzella D, Grella R, Esposito K, et al. Blood pressure and cardiac autonomic nervous system in obese type 2 diabetic patients: effect of metformin administration. Am J Hypertens. 2004;17(3):223–227.
   PubMed Web of Science ®Google Scholar